| John D Blackman, MD | |
|
500 E Main St, Ste 100, Columbus, OH 43215-5369 | |
| (614) 566-9922 | |
| (614) 566-8610 |
| Full Name | John D Blackman |
|---|---|
| Gender | Male |
| Speciality | Endocrinology |
| Experience | 40 Years |
| Location | 500 E Main St, Columbus, Ohio |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174694749 | NPI | - | NPPES |
| 0935573 | Medicaid | OH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RE0101X | Internal Medicine - Endocrinology, Diabetes & Metabolism | 35054974 (Ohio) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Riverside Methodist Hospital | Columbus, OH | Hospital |
| Grant Medical Center | Columbus, OH | Hospital |
| Berger Hospital | Circleville, OH | Hospital |
| Ohiohealth O'bleness Hospital | Athens, OH | Hospital |
| Dublin Methodist Hospital | Dublin, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Ohiohealth Corporation | 6305758426 | 1900 |
News Archive
MEDNAX, Inc. today reported non-GAAP earnings of 82 cents per share for the 2010 first quarter that was principally the result of revenue growth from acquisitions as well as operating efficiencies generated through the effective management of the Company's administrative infrastructure.
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy.
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.
› Verified 6 days ago
| Entity Name | Ohiohealth Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1578545273 PECOS PAC ID: 6305758426 Enrollment ID: O20031105000532 |
News Archive
MEDNAX, Inc. today reported non-GAAP earnings of 82 cents per share for the 2010 first quarter that was principally the result of revenue growth from acquisitions as well as operating efficiencies generated through the effective management of the Company's administrative infrastructure.
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy.
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John D Blackman, MD 5450 Frantz Rd Ste 360, Dublin, OH 43016-4141 Ph: () - | John D Blackman, MD 500 E Main St, Ste 100, Columbus, OH 43215-5369 Ph: (614) 566-9922 |
News Archive
MEDNAX, Inc. today reported non-GAAP earnings of 82 cents per share for the 2010 first quarter that was principally the result of revenue growth from acquisitions as well as operating efficiencies generated through the effective management of the Company's administrative infrastructure.
A new multi-institutional clinical trial compared outcomes of women with multiple ipsilateral breast cancer, or more than one site of disease in the same breast, who underwent breast-conserving surgery, with outcomes of those who converted to mastectomy.
Genentech, a member of the Roche Group and OSI Pharmaceuticals, a wholly owned subsidiary of Astellas U.S. Holding Inc., a holding company owned by Astellas Pharma Inc., today announced that an independent data monitoring committee has recommended that the Phase III EURTAC study be stopped early because the study met its primary endpoint.
A new portable device that utilizes artificial intelligence (AI) and biosensors can rapidly detect if cancer cells thrive after chemotherapy treatment.
› Verified 6 days ago
Sethu M. Madhavan, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 300 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3387 Fax: 614-366-0073 | |
Amrik Singh Khalsa, M.D. Endocrinology, Diabetes & Metabolism Medicare: Medicare Enrolled Practice Location: 700 Childrens Dr, Columbus, OH 43205 Phone: 614-722-2000 Fax: 614-722-4966 | |
Samuel Y. Han, M.D. Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-6255 Fax: 614-293-1456 | |
Dr. Ruchi Bhatia, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 3400 Olentangy River Rd, Columbus, OH 43202 Phone: 614-754-5500 Fax: 614-457-9519 | |
Adam T. Ramey, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 410 W 10th Ave, Columbus, OH 43210 Phone: 614-293-7499 Fax: 614-366-2360 | |
Albert J. Cook, MD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-2957 Fax: 614-685-6533 | |
Walter G. Hanel Iv, MD, PHD Endocrinology, Diabetes & Metabolism Medicare: Accepting Medicare Assignments Practice Location: 460 W 10th Ave, Columbus, OH 43210 Phone: 614-293-3196 Fax: 614-293-4812 |